Trial · NCT00422058
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in Body Weight at Week 20 | Week 0, week 20 | Calculated as mean body weight at week 20 - baseline |
| Secondary | Mean Change From Baseline in Body Weight at Week 104 | Week 0, week 104 | Calculated as mean body weight at week 104 - baseline |
| Secondary | Change From Baseline in Fasting Plasma Glucose at Week 20 | Week 0, week 20 | Calculated as mean fasting plasma glucose at week 20 - baseline |
| Secondary | Change From Baseline in Fasting Plasma Glucose at Week 104 | Week 0, week 104 | Calculated as mean fasting plasma glucose at week 104 - baseline |
| Secondary | Change From Baseline in Fasting Insulin at Week 20 | Week 0, week 20 | Calculated as mean fasting insulin at week 20 - baseline |
| Secondary | Change From Baseline in Fasting Insulin at Week 104 | Week 0, week 104 | Calculated as mean fasting insulin at week 104 - baseline |
| Secondary | Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 | Week 0, week 20 | Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 20 - baseline |
| Secondary | Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 104 | Week 0, week 104 | Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 104 - baseline |
| Secondary | Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 20 | Week 0, week 20 | Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 20-baseline. High hsCRP level is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 104 | Week 0, week 104 | Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 104- baseline. High hsCRP level is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 20 | Week 0, week 20 | Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 20-baseline. High PAI-1 is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 104 | Week 0, week 104 | Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 104-baseline. High PAI-1 is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in Fibrinogen at Week 20 | Week 0, week 20 | Calculated as mean fibrinogen at week 20 - baseline. High fibrinogen is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in Fibrinogen at Week 104 | Week 0, week 104 | Calculated as mean fibrinogen at week 104 - baseline. High fibrinogen is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in Adiponectin at Week 20 | Week 0, week 20 | Calculated as mean adiponectin at week 20-baseline. A low adiponectin level is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in Adiponectin at Week 104 | Week 0, week 104 | Calculated as mean adiponectin at week 104-baseline. A low adiponectin level is associated with greater cardiovascular risk |
| Secondary | Change From Baseline in Waist Circumference at Week 20 | Week 0, week 20 | Calculated as mean waist circumference at week 20-baseline. |
| Secondary | Change From Baseline in Waist Circumference at Week 104 | Week 0, week 104 | Calculated as mean waist circumference at week 104-baseline. |
| Secondary | Change From Baseline in Blood Pressure at Week 20 | Week 0, week 20 | Calculated as mean blood pressure at week 20-baseline. |
| Secondary | Change From Baseline in Blood Pressure at Week 104 | Week 0, week 104 | Calculated as mean blood pressure at week 104-baseline. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00422058/registered